PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31741646-11	2019	Conclusion: Early improvement and maintenance of CD4 count and viral load to normal level should be attained through streamlining and strengthening monitoring and counseling of patients on adherence to ART, Cotrimoxazole and Isoniazid drugs.	Isoniazid	225-234	CD4 molecule	Homo sapiens	49-52	
27373553-10	2017	Furthermore, we isolated isoniazid/rifampicin-specific T cells from patients, which consisted primarily of CD4+ T cells.	Isoniazid	25-34	CD4 molecule	Homo sapiens	107-110	
27373553-11	2017	Drug-specific CD4+ T cells proliferated and secreted IFN-gamma/granzyme B when stimulated with isoniazid or rifampicin, respectively.	Isoniazid	95-104	CD4 molecule	Homo sapiens	14-17	
9250234-13	1997	Patients who received isoniazid had a longer survival after stratifying for the CD4+ cell count.	Isoniazid	22-31	CD4 molecule	Homo sapiens	80-83	
32017035-10	2020	Both sex and CD4 cell count affected the bioavailability of isoniazid.	Isoniazid	60-69	CD4 molecule	Homo sapiens	13-16	
34155234-7	2021	In non-hypertensive patients, second line ART was significantly associated with viral load (OR = 8.61 (2.93-25.34)) and adverse side effects (OR = 3.50 (1.06-11.54)), while isoniazid preventive therapy was significantly associated with CD4-cell counts (OR = 1.68 (1.16-2.45)).	Isoniazid	173-182	CD4 molecule	Homo sapiens	236-239